Forget ImmunityBio: This Big?Cap Pharma Is the Safer Play on Next?Gen Cancer Therapies

2026-03-05 10:20:00 ET

Oncology is the largest therapeutic area in the biopharma industry, in terms of sales. The rapid rise in recent years of drugs to treat diabetes and manage weight loss might disrupt the traditional hierarchy, but it's safe to say that oncology will remain one of the most lucrative areas.

ImmunityBio (NASDAQ: IBRX) is a mid-cap drugmaker making waves in this niche right now; the company's shares have soared over the last 12 months. Although ImmunityBio appears promising, investors looking to bet on cancer therapies over the long run should opt for a larger, safer stock.

One that investors should consider today is Merck (NYSE: MRK) . Here's the rundown.

Continue reading